Susan Croll completed her undergraduate studies at SUNY Geneseo before attending the Neuropsychology doctoral subprogram of the Graduate Center of CUNY. For her doctoral work, she studied the effects of NMDA receptor antagonism on environmentally-induced plasticity of hippocampal dentate gyrus evoked potentials with Dr. Elizabeth Bostock. She later completed a post-doctoral fellowship with Dr. Stanley Wiegand at Regeneron Pharmaceuticals, where she studied the therapeutic potential of protein growth factors in neurological diseases. She remained at Regeneron as a scientist, accumulating 15 publications, until 2001 when she chose to explore an academic career. Dr. Croll started her own laboratory at Queens College of CUNY where she undertook a focused study of the effects of the growth factors BDNF and VEGF in epilepsy and other neurological diseases. Since then, she has published 20 articles, obtained NIH funding, mentored 12 doctoral students, and established and directed CUNY’s first Neuroscience major. Throughout her time at Queens College, she maintained her association with Regeneron as a consulting scientist, but in January of 2011 returned to Regeneron to serve as Associate Director of Pain, Addiction, and Neurology. She maintains her academic affiliation as a tenured Associate Professor of Psychology at Queens College. Dr. Croll currently serves as a standing member of the NIH-NINDS NSD-C Study Section and as a member of the NYU Science Advisory Board.
Our laboratory studies the biology of protein growth factors in the brain, with a special interest in proteins with the potential to mediate pathological interactions between the nervous, immune, and vascular systems in neurological disease. Our current diseases of most interest are epilepsy, dementia, and neurally-mediated autoimmune disease.